Neurocognitive effects of androgen deprivation therapy and new hormonal agents in a sample of patients with metastatic prostate cancer.

Ihrig, Andreas; Pernt, Pascal Marino; Zschäbitz, Stefanie; Huber, Johannes; Friederich, Hans-Christoph; Bugaj, Till J; Maatouk, Imad.

Afiliação

Ihrig A; Division of Psycho-Oncology, Department of General Internal Medicine and Psychosomatics, University Hospital Heidelberg, INF 410, 69120, Heidelberg, Germany. andreas.ihrig@med.uni-heidelberg.de.
Pernt PM; Division of Psycho-Oncology, Department of General Internal Medicine and Psychosomatics, University Hospital Heidelberg, INF 410, 69120, Heidelberg, Germany.
Zschäbitz S; Department of Medical Oncology, National Centre for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Huber J; Department of Urology, Philipps-University Marburg, Marburg, Germany.
Friederich HC; Division of Psycho-Oncology, Department of General Internal Medicine and Psychosomatics, University Hospital Heidelberg, INF 410, 69120, Heidelberg, Germany.
Bugaj TJ; Division of Psycho-Oncology, Department of General Internal Medicine and Psychosomatics, University Hospital Heidelberg, INF 410, 69120, Heidelberg, Germany.
Maatouk I; Division of Psycho-Oncology, Department of General Internal Medicine and Psychosomatics, University Hospital Heidelberg, INF 410, 69120, Heidelberg, Germany.

Int Urol Nephrol ; 55(11): 2733-2739, 2023 Nov.

Article em En | MEDLINE | ID: mdl-37466904